• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Zevra Therapeutics Inc.

    3/13/25 6:06:42 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    S-8 1 zvra20250228_s8.htm FORM S-8 zvra20250228_s8.htm

    As filed with the Securities and Exchange Commission on March 12, 2025

    Registration No. 333-



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     


     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER 

    THE SECURITIES ACT OF 1933

     


     

    Zevra Therapeutics, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

     

    20-5894398

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

     

    1180 Celebration Boulevard, Suite 103

    Celebration, FL 34747


    (Address of Principal Executive Offices) (Zip Code)

     

     Zevra Therapeutics, Inc.

    Amended and Restated 2014 Equity Incentive Plan


    (Full Title of the Plan)

     

     

    R. LaDuane Clifton, CPA

    Chief Financial Officer and Treasurer

    Zevra Therapeutics, Inc.

    1180 Celebration Boulevard, Suite 103

    Celebration, FL 34747


    (Name and Address of Agent for Service)

     

    (321) 939-3416


    (Telephone Number, Including Area Code, of Agent for Service)

     

     

    Copies to:

       

    Nathan Ajiashvili, Esq.

    Latham & Watkins LLP

    1271 Avenue of the Americas

    New York, NY 10020

    (212) 906-1200

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐     Accelerated filer ☐     Non-accelerated filer ☒     Smaller reporting company ☒     Emerging growth company ☐    

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

    2

     

     

    Explanatory Note

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,146,828 shares of the Registrant’s Common Stock to be issued pursuant to the Registrant’s Amended and Restated 2014 Equity Incentive Plan (the "A&R 2014 Plan"). A Registration Statement of the Registrant on Form S-8 relating to the A&R 2014 Plan is effective.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION

    STATEMENTS ON FORM S-8

     

    The contents of the Registration Statements on Form S-8 (File Nos. 333-203703, 333-210369, 333-216858, 333-224062, 333-230041, 333-236794, 333-252743, 333-257429, 333-270340, and 333-278444), including any amendments thereto, as filed with the Securities and Exchange Commission (the “Commission”), are incorporated herein by reference and made a part of this Registration Statement.

     

    3

     

     

    ITEM 8.     EXHIBITS

     

    Exhibit

    Number

    Description of the Exhibit

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36913) filed on April 21, 2015)

    4.2 Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant, effective as of December 23, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-36913) filed on December 23, 2020)
    4.3 Certificate of Amendment of Certificate of Incorporation of the Registrant, effective as of February 21, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-36913) filed on February 24, 2023)
    4.4 Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36913) filed on February 22, 2024)
     

    5.1*

    Opinion of Latham and Watkins LLP

    23.1*

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.

    23.3*

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

    24.1

    Power of Attorney (included on the signature page).

    99.1 Amended and Restated 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q (File No. 36913) filed on August 13, 2021)
    99.2 Form of Stock Option Grant Notice and Stock Option Agreement under 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.15 to the Registrant's Registration Statement on Form S-1 (File No. 333-202660) filed on March 11, 2015)
    99.3 Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.16 to the Registrant's Registration Statement on Form S-1 (File No. 333-202660) filed on March 11, 2015)
    99.4 Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q as filed with the SEC on May 14, 2019)
    107.1* Filing Fee Table

     

    * Filed herewith

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Celebration, State of Florida, on this 12th day of March, 2025.

     

    Zevra Therapeutics, Inc.  
         
    By: /s/ R. LaDuane Clifton  
      R. LaDuane Clifton, CPA  
      Chief Financial Officer and Treasurer  

     

    5

     

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Neil F. McFarlane and R. LaDuane Clifton, CPA and each or any one of them, his lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date

     

    /s/ Neil F. McFarlane

           

    Neil F. McFarlane

     

    President, Chief Executive Officer, and Director 

    (Principal Executive Officer)
     

    March 12, 2025

    /s/ R. LaDuane Clifton

           

    R. LaDuane Clifton, CPA

     

    Chief Financial Officer and Treasurer

    (Principal Financial Officer)

      March 12, 2025

    /s/ Timothy J. Sangiovanni

           
    Timothy J. Sangiovanni, CPA  

    Senior Vice President, Finance and Corporate Controller

    (Principal Accounting Officer)

      March 12, 2025

    /s/Thomas D. Anderson

           

    Thomas D. Anderson

     

    Director

      March 12, 2025
             
    /s/ John B. Bode        
    John B. Bode   Director   March 12, 2025

     

    /s/ Douglas W. Calder

           

    Douglas W. Calder

     

    Director

      March 12, 2025

     

    /s/ Wendy Dixon, Ph.D.

           

    Wendy Dixon, Ph.D.

     

    Director

      March 12, 2025
             
    /s/ Tamara A. Favorito        
    Tamara A. Favorito   Director   March 12, 2025
             
    /s/ Alvin Shih, M.D.        
    Alvin Shih, M.D.   Director   March 12, 2025
             
    /s/ Corey Watton        
    Corey Watton   Director   March 12, 2025

     

    6
    Get the next $ZVRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    7/2/2025$26.00Buy
    H.C. Wainwright
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00

    7/2/25 7:59:19 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

    1/8/25 8:49:26 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Zevra Therapeutics with a new price target

    Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

    10/7/24 8:28:23 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Favorito Tamara A bought $24,718 worth of shares (3,175 units at $7.79), increasing direct ownership by 442% to 3,894 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/16/25 4:15:37 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shih Alvin bought $157,800 worth of shares (20,000 units at $7.89) (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/15/25 4:07:29 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bode John B bought $45,825 worth of shares (5,000 units at $9.16), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    8/20/25 4:38:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

    CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the presentation of four posters highlighting positive new data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™. "These data highlight MIPLYFFA's potential to meaningfully stabilize disease progression across a broad spectrum of NPC patients, including adults who have historically had limited clinical data," said Adrian Quartel, M.D., FFPM, Zevra's Chief Medical Officer. "As controlled clinical tr

    2/4/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

    CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session. The opening bell ceremony can be seen live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony and on the Nasdaq MarketSite Tower at 43rd and Broadway in New York, NY. Ab

    2/2/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

    Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC) CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that four abstracts discussing data and clinical experience associated with MIPLYFFA® (arimoclomol) have been accepted for presentation at the 22nd Annual WORLDSymposium™. Dr. Caroline Hastin

    1/26/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ZVRA
    SEC Filings

    View All

    President and CEO Mcfarlane Neil F. converted options into 37,500 shares and sold $125,186 worth of shares (14,625 units at $8.56), increasing direct ownership by 6% to 387,225 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/10/26 4:49:28 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance & Corp Controller Sangiovanni Timothy J. sold $27,548 worth of shares (3,000 units at $9.18), decreasing direct ownership by 9% to 29,590 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/4/26 4:27:22 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CCO Schafer Joshua sold $96,500 worth of shares (10,500 units at $9.19), decreasing direct ownership by 14% to 62,278 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/4/26 4:27:11 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    12/17/25 4:15:39 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    12/2/25 7:34:13 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    11/20/25 4:29:38 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Financials

    Live finance-specific insights

    View All

    Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

    2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and nine months ended September 30, 2025. "Zevra is well-positioned for continued growth, driven by the strong performance of MIPLYFFA and the meaningful impact we are delivering to patients with Niemann-Pick disease type C," said Neil F.

    11/5/25 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

    CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the third quarter 2025 on Wednesday, November 5, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800) 579-2543 (

    10/27/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

    Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C Company to host conference call and webcast TODAY, August 12, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, t

    8/12/25 4:05:19 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

    CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture, as her expertise will support our continued execution of strategy and our commitment to delivering durable, sustained value for shareholders," said Tamara A. Favorito, Zevra's Chair of the Board. "We sincerely appreciate Wendy's

    12/2/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

    Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the

    5/29/25 4:35:32 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Expands Executive Leadership Team

    Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w

    6/25/24 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/12/24 5:59:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/4/24 2:15:20 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care